Imprint  |  Sitemap  |  Search

suchen
 

Here you will find our latest and archived news science 2009 in chronologically order as well as scientific publications.

For all media enquieries please contact Katja Woestenhemke (see contact details on the right). 

 

++ Latest news ++


29.04.2013

AiCuris gewinnt ALLICENSETM 2013 Breakthrough Alliance Award

Download PDF


10.03.2013

AiCuris nominated for: Deloitte Recap ALLICENSE 2013 "Breakthrough Alliance Award"

Voting closed


29.01.2013

AiCuris Surpasses 50% Enrollment Milestone in Phase II Superiority Trial for Herpes Drug Pritelivir

Download PDF


07.11.2012

After license deal for letermovir: Head-to-head phase 2 trial initiated by AiCuris to demonstrate superiority of its novel drug pritelivir vs. valacyclovir for treatment of genital herpes

Download PDF


15.10.2012

AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus

Download PDF


23.08.2012

AiCuris promising drugs against Herpes simplex (AIC316) and Human Cytomegalovirus (Letermovir, AIC246) in preparation for phase III:
Key note at International Herpesvirus Workshop Calgary, Canada

Download PDF


27.06.2012

Thomas Goldner gets Philipp Klee Price for his publication "The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase."

Download PDF

 

Katja Woestenhemke (PR/Media Contact)

AiCuris GmbH & Co. KG
Friedrich-Ebert-Str. 475
42117 Wuppertal

Phone:
+49 (0)202 317 63 - 0
Fax:
+49 (0)202 317 63 - 1177

E-Mail:
info(at)aicuris.com